Bernstein analyst Eve Burstein lowered the firm’s price target on Avantor (AVTR) to $22 from $24.50 and keeps a Market Perform rating on the shares following quarterly results. The firm says the weakness in Avantor’s Laboratory Solutions business was the big concern this quarter: The segment missed expectations and quarterly guidance, and declined year-over-year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Balanced Outlook on Avantor: Hold Rating Amidst Segment Underperformance and Strong Expense Management
- Favorable Risk-Reward Profile and Organic Growth Drive Buy Rating for Avantor
- Avantor price target lowered to $23 from $26 at Barclays
- Avantor Reports 2024 Financial Results, Shows Growth Potential
- Avantor Earnings Call: Balanced Outlook Amid Challenges